Abdominal aortic aneurysm
Conditions
Interventions
Experimental group:Rivaroxaban+pitavastatin
Control group:Aspirin+pitavastatin
Sponsors
The PLA Northern Theater Command General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1.Aged 18 to 85 years; 2.CTA diagnosis of abdominal aortic aneurysm, abdominal aortic diameter 30-55mm; 3.Plasma hypersensitive C-reactive protein >=2mg/L; 4.Voluntarily sign informed consent; 5.Patients who can tolerate aspirin and rivaroxaban.
Exclusion criteria
Exclusion criteria: 1.Diagnosed with acute coronary syndrome (unstable angina pectoris and acute myocardial infarction), stable coronary heart disease less than half a year after PCI, and acute coronary syndrome less than 1 year after PCI, taking dual antiplatelet; 2.Patients with acute congestive heart failure; 3.Patients who suffer from infectious diseases within 2 months before the selection and the infection has not been controlled for more than 1 month; 4.Diagnosed with active hepatitis or alanine aminotransferase and aspartate aminotransferase increased by more than 5 times within 1 month; 5.Severe renal insufficiency (creatinine clearance <30 ml/min); 6.Suffering from known severe progressive disease (such as malignant tumor) or disease that makes the patient extremely exhausted, and the expected survival time is <12 months; 7.Any conditions that may interfere with the research process, such as dementia, paralysis, alcoholism, etc.; 8.Pregnant women or those who intend to become pregnant; 9.Previous hereditary connective tissue disease, such as Morfan syndrome; 10.Abdominal aortic aneurysm tends to rupture or has ruptured and abdominal pain symptoms aggravate; 11.Surgery within 1 months; 12.Active severe peptic ulcer or bleeding history within the past 6 months; 13.Patients participating in other ongoing clinical studies; 14.The researchers believe that other reasons are not suitable for clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Laboratory inspection items; | — |
Secondary
| Measure | Time frame |
|---|---|
| Imageological examination;Incidence of major cardiovascular events;Laboratory inspection items;Safety index; | — |
Countries
China
Contacts
Public ContactWang Xiaozeng
The PLA Northern Theater Command General Hospital
Outcome results
None listed